menu ☰
menu ˟

FDA committee sees Spark’s retinal dystrophy gene therapy as having favorable benefit-risk profile

12 Oct 2017
An FDA advisory committee voted unanimously that Spark Therapeutics’ Luxturna gene therapy for retinal dystrophy has an overall favorable benefit-risk profile.Sixteen members of the Cellular, Tissue, and Gene Therapies Advisory Committee voted yes ...

Click here to view the full article which appeared in

IPH Logo